Welcome to our dedicated page for InfuSystem Holdings news (Ticker: INFU), a resource for investors and traders seeking the latest updates and insights on InfuSystem Holdings stock.
InfuSystem Holdings, Inc. (NYSE American: INFU) is a growing healthcare service provider specializing in delivering infusion pumps and related products and services to patients across the United States and Canada. The company is headquartered in Rochester Hills, Michigan, and operates from five strategically located facilities to ensure comprehensive coverage. InfuSystem facilitates outpatient care through a two-platform model: Patient Services and Device Solutions.
Patient Services offers a last-mile solution for clinic-to-home healthcare. This segment includes Oncology, Pain Management, Wound Therapy, and Lymphedema services. It focuses on delivering complex durable medical equipment directly to patients, ensuring they receive continuous care at home or other non-hospital settings.
Device Solutions supports the Patient Services platform by providing direct payer rentals, pump and consumable sales, and biomedical services and repair. This segment's goal is to enhance service orientation and secure additional business from its direct payer clients.
InfuSystem's innovative approach and strategic partnerships have made it a leader in the healthcare service sector. Recently, the company announced a sales and marketing partnership with Dignitana AB, a leader in scalp cooling technology. This collaboration allows InfuSystem to offer the FDA-cleared DigniCap Scalp Cooling System to help minimize hair loss for cancer patients undergoing chemotherapy. This partnership highlights InfuSystem's commitment to enhancing patient care and expanding its product offerings.
InfuSystem boasts a robust financial position, underpinned by its diversified service offerings and strong market presence. The company continues to explore new opportunities to grow and enhance its service delivery, ensuring that it remains at the forefront of the healthcare industry.
InfuSystem Holdings, Inc. (NYSE American: INFU) has announced the release of its second quarter 2022 financial results on August 4, 2022, before market opening. A subsequent conference call will be held at 9:00 a.m. Eastern Time on the same day to discuss these results. InfuSystem specializes in outpatient care services for durable medical equipment, operating two main platforms: Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME). Services include oncology, pain management, and more.
InfuSystem Holdings, Inc. (NYSE American: INFU) has announced a national sales and marketing agreement with Ventis Pharma for its Endura-Kit™, a patented local anesthetic compound. This collaboration aims to enhance pain management solutions, focusing on opioid alternatives through multi-modal approaches. The Endura-Kit™ combines three non-opioid drugs, designed to improve post-operative and chronic pain management effectively. This partnership is expected to expand InfuSystem's revenue streams and enhance their service offerings.
InfuSystem Holdings, Inc. (NYSE American: INFU) announced that its CEO Richard DiIorio, CFO Barry Steele, and COO Carrie Lachance will participate in the Craig-Hallum's 19th Annual Institutional Investor Conference on June 1, 2022. This event will be held virtually, and management will conduct one-on-one meetings throughout the day. Interested investors can reach out to Craig-Hallum or contact Lytham Partners at 602-889-9700 or via email at infu@lythampartners.com. InfuSystem is a national healthcare service provider, specializing in outpatient care for durable medical equipment.
InfuSystem Holdings, Inc. (NYSE: INFU) announced a 9% revenue increase for Q1 2022, totaling $26.8 million. Growth was driven by a 5% rise in Integrated Therapy Services and an 18% rise in Durable Medical Equipment Services. Although gross profit rose to $15.4 million, the gross margin decreased to 57.4%. InfuSystem signed a three-year Master Service Agreement with a leading medical technology company, potentially generating $10-12 million in annual revenue. Operating cash flow surged 54% to $4.1 million, but a net loss of $0.4 million was reported. The company expects 15-20% revenue growth for the full year.
InfuSystem Holdings, Inc. (NYSE American: INFU) has secured a three-year master service agreement with a leading global healthcare technology company, effective April 25, 2022. This agreement involves providing maintenance and repair services for over 300,000 infusion pumps across more than 1,200 medical facilities in North America. The estimated annual revenue from this contract is between $10 million and $12 million. The CEO emphasizes this partnership as a foundation for growth in their Durable Medical Equipment (DME) services segment.
InfuSystem Holdings, Inc. (NYSE American: INFU) will release its first quarter 2022 financial results on
InfuSystem Holdings, Inc. (NYSE American: INFU) has announced a national distribution agreement with Solo-Dex, Inc. for its continuous nerve block catheters, enhancing acute pain management capabilities. This technology allows anesthesiologists to insert catheters in two to three minutes for major procedures, potentially improving patient recovery while reducing reliance on opioids. The collaboration is aimed at capturing a significantly larger market, estimated to be ten times the current nerve catheter market. The joint effort aims to establish a new standard of care in pain management.
InfuSystem Holdings reported financial results for 2021, with net revenues at $102.4 million, a 5% increase from 2020. The fourth quarter saw revenues of $26.5 million, up 7.3% year-over-year. Despite this growth, net income dropped to $0.4 million, significantly lower than $10.7 million in Q4 2020. The gross margin decreased to 57.7%. Management anticipates 20% revenue growth in 2022, driven by pain management and a pending biomedical services contract expected to add $8-$12 million in revenue.
InfuSystem Holdings (NYSE: INFU) will announce preliminary fourth quarter and full year 2021 financial results on February 10, 2022, before the market opens. A conference call will follow the announcement at 9:00 a.m. Eastern Time to discuss these results. The company specializes in facilitating outpatient care for durable medical equipment through its Integrated Therapy Services and Durable Medical Equipment Services platforms. Interested parties can participate via phone or listen through a live webcast on the company’s investor relations website.
InfuSystem Holdings, Inc. (NYSE American: INFU) will present at the Sidoti Winter Virtual Investor Conference on January 19, 2022, at 8:30 a.m. ET. Key executives, including CEO Richard DiIorio, CFO Barry Steele, and COO Carrie Lachance, will lead the presentation.
A webcast will be available on their website, and a replay will follow the event. Investors can also engage in one-on-one meetings by contacting Lytham Partners.
FAQ
What is the current stock price of InfuSystem Holdings (INFU)?
What is the market cap of InfuSystem Holdings (INFU)?
What services does InfuSystem Holdings, Inc. provide?
What are the two platforms of InfuSystem's services?
Where is InfuSystem Holdings, Inc. headquartered?
Who are InfuSystem's recent partners?
What is the DigniCap Scalp Cooling System?
What areas does InfuSystem serve?
What is the objective of the Patient Services platform?
How does the Device Solutions platform support InfuSystem?
What are InfuSystem's business segments?
How does InfuSystem contribute to patient care?
